loading page

Application of adoptive cell therapy in hepatocellular carcinoma
  • Yujie Li,
  • Dengqiang Wu
Yujie Li
Ningbo Medical Centre Lihuili Hospital
Author Profile
Dengqiang Wu
Ningbo No 6 Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Hepatocellular carcinoma has been a serious threat to human life and health, and there is an urgent need for new treatments to prolong the overall survival time of patients. The liver plays an immunomodulatory function due to its unique physiological structural characteristics; therefore, following surgical resection and radiotherapy, immunotherapeutic options have shown great potential in the treatment of hepatocellular carcinoma in recent years, and adoptive cellular immunotherapy is developing rapidly in the treatment of hepatocellular carcinoma. In this review we summarize the latest research on adoptive cell therapy for hepatocellular carcinoma, focusing on chimeric antigen receptor (CAR) T cells and T cell receptor-engineered (TCR) T cells, and then briefly discuss tumor infiltrating lymphocytes (TILs), natural killer (NK) cells and cytokine-induced killer cells (CIKs). The aim is to provide readers with a comprehensive understanding of the current status of HCC adoptive cellular immunotherapy and new therapeutic strategies being developed, in the hope of providing new ideas for the clinical management of hepatocellular carcinoma.
27 Mar 20231st Revision Received
28 Mar 2023Review(s) Completed, Editorial Evaluation Pending
28 Mar 2023Submission Checks Completed
28 Mar 2023Assigned to Editor
04 Apr 2023Reviewer(s) Assigned
29 Apr 2023Editorial Decision: Revise Minor
09 May 20232nd Revision Received
11 May 2023Submission Checks Completed
11 May 2023Assigned to Editor
11 May 2023Review(s) Completed, Editorial Evaluation Pending
12 May 2023Reviewer(s) Assigned
06 Jun 2023Editorial Decision: Revise Minor
16 Jun 20233rd Revision Received
20 Jun 2023Review(s) Completed, Editorial Evaluation Pending
20 Jun 2023Submission Checks Completed
20 Jun 2023Assigned to Editor
21 Jun 2023Editorial Decision: Accept